Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Smart for Life (SMFL) Teams up With Diamond Creek Capital
IPO Buyers Liked it at $5.00. We Liked it at $0.85. We Love it at $0.55.
LIVE...
Video Interview: Smart for Life (SMFL) CEO A.J. Cervantes.
Excellent interview. We were at the Noble Investor Conference to see it live. And we were at the manufacturing plant this Friday....
New Report: Lion Group Holdings (LGHL) Initiating Coverage. $1.07
Massive Long-Term Potential from Singapore based Rising Fintech Star.
A Fintech that nearly 'has it all' reported impressive...
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Smart For Life to Present at The Noble Capital Markets Eighteenth Annual Investor Conference.
MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leading...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165% Potential Gain.
LIVE QUOTE
Original Report: Initiating Coverage...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Latest article
Epidemic Denial: RFK Jr. Holds Press Conference on new Autism findings from the CDC
Health and Human Services Secretary Robert F. Kennedy Jr. will be joined by officials on Wednesday to discuss the latest Autism and...
GeoVax (GOVX) Down on JFK’s Continued Scale Backs to the Vaccine Sector.
Down 20% in response to news in an 8K that the Biomedical Advanced Research and Development Authority BARDA (also once known as the...
Adding Allarity (ALLR) $0.70, to Watch List.
LIVE QUOTE
SHORT TERM CHART
Bargain Hunting?
Adding to the...
